Neumora Therapeutics (NMRA) Cash from Operations (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Cash from Operations of 46404000.0 for Q1 2026, up 21.94% year-over-year from 38054198.97 in Q1 2025, and up 3.23% quarter-over-quarter from 47955000.0 in Q4 2025.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Cash from Operations (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 46404000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 21.94% year-over-year to 46404000.0; the TTM figure through Mar 2026 stood at 193396000.0 (up 3.03% YoY), while the FY2025 annual figure was 206440000.0, down 12.85% from the prior year.
- Cash from Operations for Q1 2026 stood at 46404000.0, up from 47955000.0 in the prior quarter.
- The five-year high for Cash from Operations was 30366000.0 in Q4 2022, with the low at 59448000.0 in Q1 2025.
- The 5-year median for Cash from Operations is 47203000.0 (2023), against an average of 44958857.14.
- Peak annual rise in Cash from Operations reached 29.91% in 2024, while the deepest fall reached 81.03% in 2024.
- Neumora Therapeutics' Cash from Operations stood at 30366000.0 in 2022, then slumped by 69.41% to 51442000.0 in 2023, then increased by 2.14% to 50340000.0 in 2024, then gained by 4.74% to 47955000.0 in 2025, then grew by 3.23% to 46404000.0 in 2026.
- Business Quant data shows NMRA's Cash from Operations at 46404000.0 in Q1 2026, 47955000.0 in Q4 2025, and 46633000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Neumora Therapeutics | 243.49 Mn | 243.49 Mn | - | -39.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.53 Mn |
| Mar 31, 2026 | -46.40 Mn |
| Dec 31, 2025 | -47.96 Mn |
| Sep 30, 2025 | -46.63 Mn |
| Jun 30, 2025 | -52.40 Mn |
| Mar 31, 2025 | -59.45 Mn |
| Dec 31, 2024 | -50.34 Mn |
| Sep 30, 2024 | -33.48 Mn |
| Jun 30, 2024 | -56.16 Mn |
| Mar 31, 2024 | -42.96 Mn |
| Dec 31, 2023 | -51.44 Mn |
| Sep 30, 2023 | -47.77 Mn |
| Jun 30, 2023 | -31.02 Mn |
| Mar 31, 2023 | -33.04 Mn |
| Dec 31, 2022 | -30.37 Mn |